No Chart Data Available
No Record Found
No Record Found
Sector
PharmaceuticalsOpen
₹13.23Prev. Close
₹12.03Turnover(Lac.)
₹0.02Day's High
₹13.23Day's Low
₹13.2352 Week's High
₹13.2352 Week's Low
₹6.75Book Value
₹-1.24Face Value
₹5Mkt Cap (₹ Cr.)
7.98P/E
0EPS
0Divi. Yield
01 Sep 2025
12:00 AM
AGM
Announcement Date: 01 Sep, 2025
5 Nov 2025
12:00 AM
Board Meeting
Agenda : Audited Result
No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 3.01 | 3.01 | 3.01 | 3.01 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -3.35 | -3.02 | -3 | -3 |
Net Worth | -0.34 | -0.01 | 0 | 0 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0.06 | 0.03 |
yoy growth (%) | 0 | -100 | 91.58 | -57.78 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | 0 | 0 | 0 | 0 |
| Y/e 31 Mar( In .Cr) | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
|---|---|---|---|---|
Profit before tax | -0.07 | -0.01 | -0.05 | 0 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | -0.04 | 0.14 | -0.06 | 0.02 |
Other operating items |
| Y/e 31 Mar | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | -100 | 91.58 | -57.78 |
Op profit growth | 108.25 | -15.78 | -1,227.9 | -81.97 |
EBIT growth | 315.55 | -66.02 | -1,227.9 | -81.97 |
Net profit growth | 314.16 | -65.9 | -1,514.38 | -82.15 |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,595 | 81.88 | 3,82,693.93 | 564.22 | 1 | 4,511.27 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,054.25 | 63.93 | 1,60,721.32 | 696 | 0.49 | 2,660 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,959.75 | 62.79 | 1,34,015.93 | 597 | 0.15 | 2,707 | 249.82 |
Cipla Ltd CIPLA | 1,323.95 | 23.34 | 1,06,946.12 | 616.88 | 1.21 | 4,256.93 | 411.55 |
Dr Reddys Laboratories Ltd DRREDDY | 1,218.4 | 21.92 | 1,01,691.36 | 90.6 | 0.66 | 4,266.4 | 377.56 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman(Non Exe)&Dir(Non-Ind)
ILA RAJENDRA PATHAK
Managing Director
Amit Mukeshbhai Shah
Executive Director & CFO
Surbhit Shah
Independent Non Exe. Director
Dhruval Patel
Independent Director
Nilesh Harkesh Yadav
Company Sec. & Compli. Officer
Deepak Khandelwal
Additional Director
PRATEEK JAIN
Additional Director
Jay Chintan Patel
328 Paradise Complex,
Sayajigunj,
Gujarat - 390005
Tel: 91-265-2362966
Website: http://www.rekvinalaboratories.com
Email: rekvina@gmail.com
9 ShivShakti Indl Es,
J R Boricha Marg, Lower Parel,
Mumbai - 400 011
Tel: 022- 23016761 / 2301
Website: www.purvashare.com
Email: support@purvashare.com
Summary
Rekvina Labs Limited was incorporated on 1st November 1988. From a small domestic company at inception in middle of 80s, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company...
Read More
Reports by Rekvina Labs Ltd
What is the Rekvina Labs Ltd share price today?
What is the Market Cap of Rekvina Labs Ltd?
What is the PE and PB ratio of Rekvina Labs Ltd?
What is the 52 Week High and Low of Rekvina Labs Ltd?
What is the CAGR of Rekvina Labs Ltd?
What is the shareholding pattern of Rekvina Labs Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
